Target organ profiles in toxicity studies supporting human dosing: An assessment of recovery and chronic dosing

Regulatory Toxicology and Pharmacology

Volumn 70, Issue 1, 2014, Pages 270-285

  Horner, Steve ^a   Robinson, Sally ^a   Lees, David ^a   Callander, Richard ^a   Roberts, Ruth ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Candidate drugs; Chronic toxicology studies; Nonclinical studies; Recovery groups; Reversibility; Target organs; Toxicities; Toxicity profile

Indexed keywords

ARTICLE; BODY WEIGHT; BRAIN; CLINICAL TRIAL (TOPIC); EPIDIDYMIS; EYE; FEMUR; FLUID INTAKE; FOOD INTAKE; GALLBLADDER; HEART; HISTOPATHOLOGY; HUMAN; INCIDENCE; KIDNEY; LIVER; LUNG; NONHUMAN; ORGAN WEIGHT; PANCREAS; PRIORITY JOURNAL; PROSTATE; RISK ASSESSMENT; SKELETAL MUSCLE; SKIN; SPLEEN; STOMACH; TARGET ORGAN; TESTIS; THYMUS; THYROID GLAND; TOOTH; TOXICITY TESTING; URINALYSIS; UTERUS; VAGINA; ANIMAL; DRUG ADMINISTRATION; DRUG SCREENING; PROCEDURES; SPECIES DIFFERENCE;

NEW DRUG;

ANIMALS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; RISK ASSESSMENT; SPECIES SPECIFICITY; TOXICITY TESTS;

EID: 84908308106     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2014.07.008     Document Type: Article

References (19)

1. Baldrick P. Safety evaluation to support first-in-man investigations II: toxicology studies. Regul. Toxicol. Pharmacol. 2008, 51:237-243.
2. Ballet F. Hepatotoxicity in drug development: detection, significance and solutions. J. Hepatol. 1997, 26(Suppl. 2):26-36.
3. Davies, W., Stephenson, L., Redfern, W., Storey, S., Billger, M., Betts C., Jones, H., 2014. Hypoglycaemic peripheral polyneuropathy in rodents given small molecule glucokinase activators. Toxicol. Pathol., in press.
4. Greaves P., Williams A., Eve M. First dose of potential new medicines to humans: how animals help. Nat. Rev. Drug Discovery 2004, 3:226-236.
5. Haruyama E., Suda M., Ayukawa Y., Kamura K., Mizutamari M., Ooshima Y., Tanimoto A. Testicular development in cynomolgus monkeys. Toxicol. Pathol. 2012, 40:935-942.
6. Heywood R. Target organ toxicity. Toxicol. Lett. 1981, 8:349-358.
7. Horner S., Ryan D., Robinson S., Callander R., Stamp K., Roberts R. Target organ toxicities in studies conducted to support first time in man dosing: an analysis across species and therapy areas. Regul. Toxicol. Pharmacol. 2013, 65:334-343.
8. ICH Guideline M3(R2), 2009. Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. (last accessed 01 April 2014). http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-guidelines.html.
9. ICH Guideline S6(R1), 2011. Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. (last accessed 01 April 2014). http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html.
10. ICH Guideline S9, 2009. Nonclinical Evaluation for Anticancer Pharmaceuticals. (last accessed 01 April 2014). http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html.
11. ICM M3 (R2) Q&A, 2013. Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. Questions and Answers (R2). Feb 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292340.pdf.
12. Lanning L., Creasy D., Chapin R., Mann P., Barlow N., Regan K., Goodman D. Recommended approaches for the evaluation of testicular and epididymal toxicity. Toxicol. Pathol. 2002, 30:507-520.
13. NC3Rs, 2012: National Centre for the Replacement, Refinement & Reduction of Animals in Research, 2012. Reducing the use of recovery animals in pharmaceutical development. (last accessed 11 November 2013). http://www.nc3rs.org.uk/news.asp?id=1814.
14. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berger B., Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Reg. Toxicol. Pharmacol. 2000, 32:56-67.
15. Pandher K., Leach N.W., Burns-Naas L.A. Appropriate use of recovery groups in nonclinical toxicity studies: value in a science-driven case-by-case approach. Vet. Pathol. 2012, 49:357-361.
16. Senderowicz A.M. Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer. Clin. Cancer Res. 2010, 16:1719-1725.
17. Sidenius P., Jakobsen J. Peripheral neuropathy in rats induced by insulin treatment. Diabetes 1983, 32:383-386.
18. Sparrow S.S., Robinson S., Bolam S., Bruce C., Danks A., Everett D., Fulcher S., Hill R.E., Palmer H., Scott E.W., Chapman K.L. Opportunities to minimise animal use in pharmaceutical regulatory general toxicology: a cross-company review. Regul. Toxicol. Pharmacol. 2011, 61:222-229.
19. Zühlke U., Weinbauer G. The common marmoset (Callithrix jacchus) as a model in toxicology. Toxicol. Pathol. 2003, 31:123-127.